Exit stage left for senior leaders at Intrexon

Intrexon ($XON) has announced the departure of its chief operating officer, Krish Krishnan, and SVP of product development Suma Krishnan, effective immediately. The Virginia-based company, which focuses on synthetic biology, said in a statement this was because of the "successful growth of the company"--and also because it has hired new senior members to run the five business sectors across the company. The two roles will now be spread among a number of existing officers, with Joel Liffmann, SVP of finance, taking on primary responsibility for operating divisions. Randal Kirk, chairman and CEO of Intrexon, said: "I would like to thank Krish and Suma for their contributions to the company." Release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.